Clinical Trial Update: This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis [EARLY_Phase 1]

View source ↗

Summary

An open-label early Phase 1 trial evaluating GC012F for safety and efficacy in patients with multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GC012F

Snippet

Sponsor: Huashan Hospital | Conditions: Multiple Sclerosis | EARLY_Phase 1 | Status: WITHDRAWN